{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:31:56Z","timestamp":1782786716536,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T00:00:00Z","timestamp":1366156800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s00403-013-1355-4","type":"journal-article","created":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T11:17:48Z","timestamp":1366111068000},"page":"67-74","source":"Crossref","is-referenced-by-count":21,"title":["A prospective study on clinical response and cell-mediated immunity of pemphigus patients treated with rituximab"],"prefix":"10.1007","volume":"306","author":[{"given":"Y. A.","family":"Leshem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hodak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Waitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Israeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Eskin-Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Mimouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,17]]},"reference":[{"key":"1355_CR1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10165-012-0621-1","volume":"23","author":"M Akimoto","year":"2013","unstructured":"Akimoto M, Yunoue S, Otsubo H et al (2013) Assessment of peripheral blood CD4+\u00a0adenosine triphosphate activity in patients with\u00a0rheumatoid arthritis. Mod Rheumatol 23:19\u201327","journal-title":"Mod Rheumatol"},{"key":"1355_CR2","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0092-8674(91)90360-B","volume":"67","author":"M Amagai","year":"1991","unstructured":"Amagai M, Klaus-Kovtun V, Stanley JR (1991) Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 67:869\u2013877","journal-title":"Cell"},{"key":"1355_CR3","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/jid.2010.91","volume":"130","author":"S Beissert","year":"2010","unstructured":"Beissert S, Mimouni D, Kanwar AJ et al (2010) Treating\u00a0pemphigus vulgaris with prednisone\u00a0and\u00a0mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol 130:2041\u20132048","journal-title":"J Invest Dermatol"},{"key":"1355_CR4","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113:4834\u20134840","journal-title":"Blood"},{"key":"1355_CR5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jaad.2011.11.007","volume":"67","author":"G Cianchini","year":"2012","unstructured":"Cianchini G, Lupi F, Masini C et al (2012) Therapy with\u00a0rituximab\u00a0for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol 67:617\u2013622","journal-title":"J Am Acad Dermatol"},{"key":"1355_CR6","doi-asserted-by":"crossref","unstructured":"Cohen SB, Emery P, Greenwald MW, et al., REFLEX Trial Group (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793\u20132806","DOI":"10.1002\/art.22025"},{"key":"1355_CR7","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A, DANCER Study Group (2006) The efficacy and safety of\u00a0rituximab\u00a0in patients with active\u00a0rheumatoid arthritis\u00a0despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390\u20131400","journal-title":"Arthritis Rheum"},{"key":"1355_CR8","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1038\/jid.2008.172","volume":"128","author":"R Eming","year":"2008","unstructured":"Eming R, Nagel A, Wolff-Franke S et al (2008) Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol 128:2850\u20132858","journal-title":"J Invest Dermatol"},{"issue":"Suppl 1","key":"1355_CR9","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1136\/ard.2009.123885","volume":"69","author":"DE Furst","year":"2009","unstructured":"Furst DE, Keystone EC, Fleischmann R et al (2009) Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 69(Suppl 1):i2\u2013i29","journal-title":"Ann Rheum Dis"},{"key":"1355_CR10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.trim.2010.11.006","volume":"24","author":"S Ge","year":"2011","unstructured":"Ge S, Pao A, Vo A et al (2011) Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab. Transpl Immunol 24:142\u2013148","journal-title":"Transpl Immunol"},{"key":"1355_CR11","doi-asserted-by":"crossref","first-page":"e18506","DOI":"10.1371\/journal.pone.0018506","volume":"20","author":"A Haghikia","year":"2011","unstructured":"Haghikia A, Perrech M, Pula B et al (2011) Functional energetics of CD4+\u00a0-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. PLoS ONE 20:e18506","journal-title":"PLoS ONE"},{"key":"1355_CR12","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1097\/TP.0b013e3181cbabe6","volume":"89","author":"M Israeli","year":"2010","unstructured":"Israeli M, Ben-Gal T, Yaari V et al (2010) Individualized immune monitoring of cardiac transplant recipients by noninvasive longitudinal cellular immunity tests. Transplantation 89:968\u2013976","journal-title":"Transplantation"},{"key":"1355_CR13","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.cca.2012.01.033","volume":"413","author":"M Israeli","year":"2012","unstructured":"Israeli M, Klein T, Brandhorst G, Oellerich M (2012) Confronting the challenge: individualized immune monitoring after organ transplantation using the cellular immune function assay. Clin Chim Acta 413:1374\u20131378","journal-title":"Clin Chim Acta"},{"key":"1355_CR14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","volume":"357","author":"P Joly","year":"2007","unstructured":"Joly P, Mouquet H, Roujeau J-C et al (2007) A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 357:545\u2013552","journal-title":"N Engl J Med"},{"key":"1355_CR15","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","volume":"65","author":"M Kasperkiewicz","year":"2011","unstructured":"Kasperkiewicz M, Shimanovich I, Ludwig RJ et al (2011) Rituximab for treatment-refractory\u00a0pemphigus\u00a0and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 65:552\u2013558","journal-title":"J Am Acad Dermatol"},{"key":"1355_CR16","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1365-2133.2011.10411.x","volume":"165","author":"JH Kim","year":"2011","unstructured":"Kim JH, Kim YH, Kim MR, Kim SC (2011) Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol 165:646\u2013651","journal-title":"Br J Dermatol"},{"key":"1355_CR17","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/01.tp.0000234837.02126.70","volume":"82","author":"RJ Kowalski","year":"2006","unstructured":"Kowalski RJ, Post DR, Mannon RB et al (2006) Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 82:663\u2013668","journal-title":"Transplantation"},{"key":"1355_CR18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1034\/j.1399-0012.2003.00013.x","volume":"17","author":"RJ Kowalski","year":"2003","unstructured":"Kowalski RJ, Post D, Schneider MC et al (2003) Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 17:77\u201388","journal-title":"Clin Transplant"},{"key":"1355_CR19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","volume":"54","author":"MJ Leandro","year":"2006","unstructured":"Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC (2006) Repopulation of B lymphocytes in peripheral blood following B lymphocyte depletion with rituximab in rheumatoid arthritis. Arthritis Rheum 54:613\u2013620","journal-title":"Arthritis Rheum"},{"key":"1355_CR20","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jaad.2012.08.010","volume":"68","author":"YA Leshem","year":"2013","unstructured":"Leshem YA, Hodak E, David M et al (2013) Successful treatment of pemphigus with bi-weekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol 68:404\u2013411","journal-title":"J Am Acad Dermatol"},{"key":"1355_CR21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0733-8635(05)70010-3","volume":"16","author":"RS Lester","year":"1998","unstructured":"Lester RS, Knowles SR, Shear NH (1998) The risks of systemic corticosteroid use. Dermatol Clin 16:277\u2013278","journal-title":"Dermatol Clin"},{"key":"1355_CR22","doi-asserted-by":"crossref","unstructured":"Martin LK, Werth V, Villanueva E, et al (2009) Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev (1):CD006263","DOI":"10.1002\/14651858.CD006263.pub2"},{"key":"1355_CR23","first-page":"1763","volume":"12","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, White CA, Grillo-Lopez AJ, Maloney DG (1998) Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Williston Park) 12:1763\u20131769","journal-title":"Oncology (Williston Park)"},{"key":"1355_CR24","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/jid.2008.178","volume":"128","author":"H Mouquet","year":"2008","unstructured":"Mouquet H, Musette P, Gougeon ML et al (2008) B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 128:2859\u20132869","journal-title":"J Invest Dermatol"},{"key":"1355_CR25","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","volume":"58","author":"DF Murrell","year":"2008","unstructured":"Murrell DF, Dick S, Ahmed AR et al (2008) Consensus statement on definitions of disease endpoints and therapeutic response for pemphigus. J Am Acad Dermatol 58:1043\u20131046","journal-title":"J Am Acad Dermatol"},{"key":"1355_CR26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/jid.2008.192","volume":"129","author":"A Nagel","year":"2009","unstructured":"Nagel A, Hertl M, Eming R (2009) B-cell-directed therapy for inflammatory skin diseases. J Invest Dermatol 129:289\u2013301","journal-title":"J Invest Dermatol"},{"key":"1355_CR27","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/MOT.0b013e32832c5999","volume":"14","author":"P Nickel","year":"2009","unstructured":"Nickel P, Bestard O, Volk HD, Reinke P (2009) Diagnostic value of T-cell monitoring assays in kidney transplantation. Curr Opin Organ Transplant 14:426\u2013431","journal-title":"Curr Opin Organ Transplant"},{"key":"1355_CR28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1046\/j.1523-1747.2000.00840.x","volume":"114","author":"K Nishifuji","year":"2000","unstructured":"Nishifuji K, Amagai M, Kuwana M et al (2000) Detection\u00a0of\u00a0antigen-specific\u00a0B cells in patients\u00a0with\u00a0pemphigus vulgaris\u00a0by\u00a0enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production. J Invest Dermatol 114:88\u201394","journal-title":"J Invest Dermatol"},{"key":"1355_CR29","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1057\/jors.2009.49","volume":"61","author":"M Parzen","year":"2010","unstructured":"Parzen M, Lipsitz S, Metters R, Fitzmaurice G (2010) Correlation when data are missing. J Oper Res Soc 61:1049\u20131056","journal-title":"J Oper Res Soc"},{"key":"1355_CR30","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1038\/jid.2009.72","volume":"129","author":"M Rosenbach","year":"2009","unstructured":"Rosenbach M, Murell DF, Bystryn JC et al (2009) Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol 129:2404\u20132410","journal-title":"J Invest Dermatol"},{"key":"1355_CR31","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1067\/mjd.2002.126273","volume":"47","author":"TG Salopek","year":"2002","unstructured":"Salopek TG, Logsetty S, Tredget EE (2002) Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 47:785\u2013788","journal-title":"J Am Acad Dermatol"},{"key":"1355_CR32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1749-6632.2009.04744.x","volume":"1173","author":"E Schmidt","year":"2009","unstructured":"Schmidt E, Goebeler M, Zillikens D (2009) Rituximab in severe pemphigus. Ann NY Acad Sci 1173:683\u2013691","journal-title":"Ann NY Acad Sci"},{"key":"1355_CR33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1128\/CDLI.7.2.307-311.2000","volume":"7","author":"PR Sottong","year":"2000","unstructured":"Sottong PR, Rosebrock JA, Britz JA, Kramer TR (2000) Measurement of T lymphocyte responses in whole-blood cultures using newly synthesized DNA and ATP. Clin Diagn Lab Immunol 7:307\u2013311","journal-title":"Clin Diagn Lab Immunol"},{"key":"1355_CR34","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0065-2776(08)60503-9","volume":"53","author":"JR Stanley","year":"1993","unstructured":"Stanley JR (1993) Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion. Adv Immunol 53:291\u2013325","journal-title":"Adv Immunol"},{"key":"1355_CR35","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1172\/JCI114036","volume":"83","author":"JR Stanley","year":"1989","unstructured":"Stanley JR (1989) Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases. J Clin Invest 83:1443\u20131448","journal-title":"J Clin Invest"},{"key":"1355_CR36","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.4049\/jimmunol.182.3.1740","volume":"182","author":"H Takahashi","year":"2009","unstructured":"Takahashi H, Kuwana M, Amagai M (2009) A single helper\u00a0T\u00a0cell\u00a0clone\u00a0is sufficient to commit\u00a0polyclonal\u00a0naive B cells to produce pathogenic IgG in experimental pemphigus vulgaris. J Immunol 182:1740\u20131745","journal-title":"J Immunol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-013-1355-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00403-013-1355-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-013-1355-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T08:08:58Z","timestamp":1595664538000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-013-1355-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,17]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["1355"],"URL":"https:\/\/doi.org\/10.1007\/s00403-013-1355-4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718227165.793491084","asserted-by":"object"}]},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,17]]}}}